CIK: 0001274413
Total reported value
$120.7M
Reporting period: 2026-03-31 · Number of holdings: 77
SECTORAL ASSET MANAGEMENT INC disclosed 77 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $120.7M and a quarterly turnover rate of 29.6%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "S"
Sectoral Asset Management INC's disclosed holdings carry a Herfindahl concentration index of 0.036 — mathematically equivalent to about 28 equally-sized positions, well below its 77 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.34), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 57% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add EVMN
0.0% $3.5M
Add GILD
+53.7% $1.9M
Trim LLY
-12.7% -$2.0M
Add INSM
+75.9% $1.4M
Trim ABBV
-27.4% -$1.2M
Trim GPCR
-40.9% -$949.5K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EVMN | Evommune INC | Stock-Other | 11.22% | +3.14% | — | |
| 2 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 7.87% | +0.53% | -9.14% | |
| 3 | SI | Shoulder Innovations INC | Stock-Other | 5.18% | -0.46% | -12.60% | |
| 4 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.84% | -1.43% | -12.67% | |
| 5 | JNJ | Johnson & Johnson | Stock-Healthcare | 3.69% | +0.32% | -10.26% | |
| 6 | GILD | Gilead Sciences INC | Stock-Healthcare | 3.42% | +1.66% | +53.70% | |
| 7 | UNH | Unitedhealth Group INC | Stock-Healthcare | 3.35% | -0.25% | +10.02% | |
| 8 | AMGN | Amgen INC | Stock-Healthcare | 2.91% | -0.52% | -29.53% | |
| 9 | VRTX | Vertex Pharmaceuticals INC | Stock-Healthcare | 2.86% | — | -12.47% | |
| 10 | INSM | Insmed INC | Stock-Healthcare | 2.80% | +1.24% | +75.89% | |
| 11 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.27% | +0.32% | +23.15% | |
| 12 | ABBV | Abbvie INC | Stock-Healthcare | 2.20% | -0.88% | -27.38% | |
| 13 | ABT | Abbott Laboratories | Stock-Healthcare | 2.18% | -0.18% | +8.85% | |
| 14 | MRK | Merck & Co. INC. | Stock-Healthcare | 2.14% | +0.33% | +0.37% | |
| 15 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.06% | -0.24% | -21.43% | |
| 16 | ISRG | Intuitive Surgical INC | Stock-Healthcare | 2.00% | -0.20% | +8.25% | |
| 17 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.81% | -0.30% | +25.90% | |
| 18 | BNTX | Biontech Se-adr | Stock-Other | 1.69% | +0.38% | +28.73% | |
| 19 | SYK | Stryker CORP | Stock-Healthcare | 1.60% | -0.25% | -10.32% | |
| 20 | DHR | Danaher CORP | Stock-Healthcare | 1.51% | -0.43% | -9.25% | |
| 21 | TMO | Thermo Fisher Scientific INC | Stock-Healthcare | 1.43% | -0.38% | -10.05% | |
| 22 | DXCM | Dexcom INC | Stock-Healthcare | 1.21% | -0.32% | -19.06% | |
| 23 | IQV | Iqvia Holdings INC | Stock-Healthcare | 1.17% | +1.17% | NEW | |
| 24 | SMMT | Summit Therapeutics INC | Stock-Other | 1.16% | — | -12.57% | |
| 25 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.15% | — | +0.51% | |
| 26 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.06% | +1.06% | NEW | |
| 27 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.95% | +0.28% | -0.75% | |
| 28 | VERA | Vera Therapeutics INC | Stock-Other | 0.90% | -0.60% | -30.62% | |
| 29 | RCUS | Arcus Biosciences INC | Stock-Other | 0.86% | -0.23% | -20.85% | |
| 30 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.84% | — | -28.33% | |
| 31 | MDT | Medtronic plc | Stock-Healthcare | 0.80% | +0.80% | NEW | |
| 32 | TRVI | Trevi Therapeutics INC | Stock-Other | 0.78% | — | -11.64% | |
| 33 | COGT | Cogent Biosciences INC | Stock-Other | 0.75% | -0.18% | -32.26% | |
| 34 | MLYS | Mineralys Therapeutics INC | Stock-Other | 0.74% | -0.18% | -0.02% | |
| 35 | ALNY | Alnylam Pharmaceuticals INC | Stock-Healthcare | 0.72% | -0.23% | -22.74% | |
| 36 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 0.71% | -0.26% | -23.53% | |
| 37 | RAPP | Rapport Therapeutics INC | Stock-Other | 0.69% | -0.26% | -34.69% | |
| 38 | NKTR | Nektar Therapeutics | Stock-Other | 0.68% | +0.22% | -19.53% | |
| 39 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 0.65% | -0.38% | -48.24% | |
| 40 | ARDX | Ardelyx INC | Stock-Other | 0.65% | +0.65% | NEW | |
| 41 | PFE | Pfizer INC | Stock-Healthcare | 0.64% | — | +1.29% | |
| 42 | BOLD | Boundless Bio INC | Stock-Other | 0.62% | — | — | |
| 43 | ASND | Ascendis Pharma A/S | Stock-Other | 0.60% | — | -13.95% | |
| 44 | AVBP | Arrivent Biopharma INC | Stock-Other | 0.60% | — | -21.54% | |
| 45 | GPCR | Structure Therapeutics INC | Stock-Other | 0.59% | -0.74% | -40.93% | |
| 46 | ✓ | Immatics NV | Stock-Other | 0.57% | — | +6.05% | |
| 47 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 0.57% | — | -27.48% | |
| 48 | SPRY | Ars Pharmaceuticals INC | Stock-Other | 0.56% | +0.28% | +165.58% | |
| 49 | ONC | Beone Medicines Ltd-adr | Stock-Other | 0.52% | — | -29.83% | |
| 50 | TECX | Tectonic Therapeutic INC | Stock-Other | 0.52% | -0.19% | -54.90% |
Performance for Q3 2026
+0.1%
Performance Last 4 Quarters
-3.7%
Based on 64% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 77 | $120.7M | 30 | |
| 2025-12-31 | 74 | $124.8M | 65 | |
| 2025-09-30 | 82 | $162.0M | 91 | |
| 2025-06-30 | 94 | $151.5M | 0 | |
| 2025-03-31 | 84 | $128.5M | 100 | |
| 2024-12-31 | 86 | $149.8M | 0 | |
| 2024-09-30 | 90 | $169.3M | 0 | |
| 2024-06-30 | 97 | $246.1M | 0 | |
| 2024-03-31 | 92 | $254.4M | 0 | |
| 2023-12-31 | 104 | $232.2M | 0 | |
| 2023-09-30 | 123 | $513.5M | 0 | |
| 2023-06-30 | 121 | $599.8M | 0 | |
| 2023-03-31 | 118 | $520.3M | 0 | |
| 2022-12-31 | 120 | $516.8M | 0 | |
| 2022-09-30 | 109 | $507.6M | 0 | |
| 2022-06-30 | 112 | $496.3M | 0 | |
| 2022-03-31 | 106 | $563.3M | 0 | |
| 2021-12-31 | 108 | $664.4M | 0 | |
| 2021-09-30 | 127 | $1.2B | 0 | |
| 2021-06-30 | 127 | $1.2B | 100 | |
| 2021-03-31 | 113 | $1.3B | 77 | |
| 2020-12-31 | 97 | $1.4B | 65 | |
| 2020-09-30 | 88 | $1.2B | 71 | |
| 2020-06-30 | 191 | $1.1B | 91 | |
| 2020-03-31 | 65 | $520.9M | 53 | |
| 2019-12-31 | 65 | $670.2M | 73 | |
| 2019-09-30 | 63 | $579.6M | 53 | |
| 2019-06-30 | 92 | $836.3M | 32 | |
| 2019-03-31 | 106 | $831.4M | 38 | |
| 2018-12-31 | 104 | $735.6M | 46 | |
| 2018-09-30 | 168 | $941.9M | 40 | |
| 2018-06-30 | 67 | $894.4M | 45 | |
| 2018-03-31 | 68 | $912.1M | 48 | |
| 2017-12-31 | 67 | $800.3M | 48 | |
| 2017-09-30 | 62 | $776.3M | 56 | |
| 2017-06-30 | 61 | $914.4M | 45 | |
| 2017-03-31 | 65 | $856.3M | 61 | |
| 2016-12-31 | 55 | $902.7M | 50 | |
| 2016-09-30 | 56 | $1.0B | 38 | |
| 2016-06-30 | 64 | $968.4M | 94 | |
| 2016-03-31 | 81 | $2.1B | 45 | |
| 2015-12-31 | 75 | $2.3B | 35 | |
| 2015-09-30 | 77 | $2.2B | 31 | |
| 2015-06-30 | 91 | $2.4B | 51 | |
| 2015-03-31 | 77 | $2.6B | 47 | |
| 2014-12-31 | 64 | $2.2B | 34 | |
| 2014-09-30 | 66 | $2.4B | 30 | |
| 2014-06-30 | 64 | $2.4B | 34 | |
| 2014-03-31 | 64 | $2.4B | 32 | |
| 2013-12-31 | 59 | $2.3B | 41 | |
| 2013-09-30 | 55 | $2.1B | 77 | |
| 2013-06-30 | 56 | $3.4B | 0 |
Sectoral Asset Management INC's most significant position changes for 2026-03-31: New buy: Iqvia Holdings INC (IQV); Sold out: Astrazeneca Plc-spons Adr (AZNN); New buy: Bristol-myers Squibb Co (BMY); New buy: Medtronic plc (MDT); Sold out: Ventyx Biosciences INC (VTYXUSD).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EVMN | Evommune INC | +3.1% | — | Unchanged |
| 2 | GILD | Gilead Sciences INC | +1.7% | +53.70% | Add |
| 3 | INSM | Insmed INC | +1.2% | +75.89% | Add |
| 4 | CTNM | Contineum Therapeutics Inc-a | +0.5% | -9.14% | Trim |
| 5 | BNTX | Biontech Se-adr | +0.4% | +28.73% | Add |
| 6 | MRK | Merck & Co. INC. | +0.3% | +0.37% | Add |
| 7 | ARGX | Argenx Se - Adr | +0.3% | +23.15% | Add |
| 8 | JNJ | Johnson & Johnson | +0.3% | -10.26% | Trim |
| 9 | SPRY | Ars Pharmaceuticals INC | +0.3% | +165.58% | Add |
| 10 | UTHR | United Therapeutics CORP | +0.3% | -0.75% | Trim |
| 11 | NKTR | Nektar Therapeutics | +0.2% | -19.53% | Trim |
| 12 | ABT | Abbott Laboratories | -0.2% | +8.85% | Add |
| 13 | COGT | Cogent Biosciences INC | -0.2% | -32.26% | Trim |
| 14 | MLYS | Mineralys Therapeutics INC | -0.2% | -0.02% | Trim |
| 15 | QURE | uniQure N.V. | -0.2% | -4.38% | Trim |
| 16 | OMDA | Omada Health INC | -0.2% | -29.81% | Trim |
| 17 | TECX | Tectonic Therapeutic INC | -0.2% | -54.90% | Trim |
| 18 | ISRG | Intuitive Surgical INC | -0.2% | +8.25% | Add |
| 19 | INSP | Inspire Medical Systems INC | -0.2% | +0.35% | Add |
| 20 | ALNY | Alnylam Pharmaceuticals INC | -0.2% | -22.74% | Trim |
| 21 | RCUS | Arcus Biosciences INC | -0.2% | -20.85% | Trim |
| 22 | REGN | Regeneron Pharmaceuticals | -0.2% | -21.43% | Trim |
| 23 | UNH | Unitedhealth Group INC | -0.3% | +10.02% | Add |
| 24 | SYK | Stryker CORP | -0.3% | -10.32% | Trim |
| 25 | TARS | Tarsus Pharmaceuticals INC | -0.3% | -23.53% | Trim |
| 26 | RAPP | Rapport Therapeutics INC | -0.3% | -34.69% | Trim |
| 27 | RDNT | Radnet INC | -0.3% | -27.28% | Trim |
| 28 | BSX | Boston Scientific CORP | -0.3% | +25.90% | Add |
| 29 | DXCM | Dexcom INC | -0.3% | -19.06% | Trim |
| 30 | TMO | Thermo Fisher Scientific INC | -0.4% | -10.05% | Trim |
| 31 | SNDX | Syndax Pharmaceuticals INC | -0.4% | -48.24% | Trim |
| 32 | DHR | Danaher CORP | -0.4% | -9.25% | Trim |
| 33 | SI | Shoulder Innovations INC | -0.5% | -12.60% | Trim |
| 34 | AMGN | Amgen INC | -0.5% | -29.53% | Trim |
| 35 | VERA | Vera Therapeutics INC | -0.6% | -30.62% | Trim |
| 36 | GPCR | Structure Therapeutics INC | -0.7% | -40.93% | Trim |
| 37 | ABBV | Abbvie INC | -0.9% | -27.38% | Trim |
| 38 | LLY | Eli Lilly & Co | -1.4% | -12.67% | Trim |
| 39 | IQV | Iqvia Holdings INC | — | NEW | New buy |
| 40 | AZNN | Astrazeneca Plc-spons Adr | — | EXIT | Sold out |
| 41 | BMY | Bristol-myers Squibb Co | — | NEW | New buy |
| 42 | MDT | Medtronic plc | — | NEW | New buy |
| 43 | VTYXUSD | Ventyx Biosciences INC | — | EXIT | Sold out |
| 44 | ARDX | Ardelyx INC | — | NEW | New buy |
| 45 | LENZ | Lenz Therapeutics INC | — | EXIT | Sold out |
| 46 | AM6 | Amicus Therapeutics INC | — | EXIT | Sold out |
| 47 | CARL | Carlsmed INC | — | EXIT | Sold out |
| 48 | AGMB | Agomab Therapeutics NV | — | NEW | New buy |
| 49 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 50 | TEM | Tempus Ai Inc-cl A | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-09 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-14 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-11 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-12 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-10 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-10 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-10 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-11 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-14 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-12 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-13 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-13 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-13 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-12 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-14 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-12 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-13 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-13 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-10 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-10 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-12 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-13 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-12 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-13 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-13 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-14 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-13 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-13 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-14 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-12 | 13F-HR | View on EDGAR |
| 2013-09-30 | 2013-11-13 | 13F-HR | View on EDGAR |
| 2013-06-30 | 2013-08-12 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002069207
Total reported value
$120.7M
113 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002099097
Total reported value
$120.7M
295 stks
2026-06-30
AUM within 0.0% of this institution
CIK 0001580162
Total reported value
$120.7M
29 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0000315032
Total reported value
$126.9B
197 stks
2026-03-31
2 of the top 5 holdings overlap, including Eli Lilly & Co
CIK 0000872259
Total reported value
$19.8B
327 stks
2026-03-31
2 of the top 5 holdings overlap, including Johnson & Johnson
CIK 0001327944
Total reported value
$321.1M
153 stks
2026-06-30
2 of the top 5 holdings overlap, including Eli Lilly & Co